

Patient Information	Specimen Information	Client Information

COMMENTS: FASTING:

Cardio IQ®

GENETIC CARDIOVASCULAR MARKERS

Lab:

Test Name	Result	Comments (See Guidance Statements)
APOE GENOTYPE	3/3	Apo E3 Carrier. Most common (normal) genotype.

SPECIMEN:

Patient Information	Specimen Information	Client Information

CARDIOVASCULAR GENETICS DETAIL REPORT

GUIDANCE SUMMARY:

CARDIO IQ APOE GENOTYPE

Lab:

APO E GENOTYPE

3/3

GUIDANCE STATEMENTS

Indication for testing: Aid in the assessment of cardiovascular disease risk.
 Interpretation: This patient has the ApoE genotype of E3/E3, the most common (normal) genotype. The E3/E3 genotype is associated with slightly lower LDL-C levels and lower risk of coronary heart disease (CHD) compared to individuals who carry the E4 allele.

REVIEWER

Laboratory testing supervised and results monitored by

General (Cardiovascular Genetics)

GENERAL GUIDANCE

1. Non genetic factors contribute to coronary heart disease (CHD), cardiovascular disease (CVD), or myocardial infarction (MI) risk. Examples of such factors include smoking, hypertension, age, diabetes, elevated blood lipid levels, obesity and sedentary lifestyle.
2. Other genetic factors (e.g. family history of heart disease) may contribute to CHD, CVD, or MI risk.
3. These genetic test results should be considered in context of other clinical criteria by a qualified physician. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
4. Genetic consultation for this individual may be helpful in understanding the genetic implications of these test results and management options.

METHOD

Real-Time Polymerase Chain Reaction (PCR). Analytic sensitivity and specificity of the genetic assays using this platform exceed 99.9%.

LIMITATIONS

Although rare, false positive or false negative results may occur. All results should be interpreted in context of clinical findings, relevant history, and other laboratory data.
 This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

SPECIMEN: